How AI can accelerate the search for treatments for emerging and intractable diseases
Artificial intelligence (AI) models and algorithms can save time and money in the search for drug candidates for emerging diseases, including COVID-19.
Founded in 2013, BenevolentAI is a global leader in the development and application of artificial intelligence (AI) for scientific innovation. BenevolentAI has been building and applying AI to the world’s most valuable resource, data, to generate and probe science’s "hidden knowledge". BenevolentAI currently operates two distinct business units: BenevolentBio, which applies BenevolentAI’s technology in human health and the exploration of further bioscience applications; and BenevolentTech, which refines and develops the company’s technology and aims to replicate its initial success across wider applications.